Dyslipidaemia is an independent risk factor for cardiovascular diseases (CVD). There is a strong relationship between elevated levels of plasma cholesterol and atherosclerotic vascular disease. By reducing the total cholesterol and LDL cholesterol to below critical levels, there is a marked reduction in cardiovascular mortality. Hence  this  clinical study was undertaken to compare efficacy  of the fixed dose combination of Atorvastatin with vitamin D and Atorvastatin alone on lipid profile  in patients with chronic kidney disease . METHODS: 60 patients with dyslipedemia and chronic kidney disease were selected and divided into two groups of 30 each atorvastatin and atorvastatin with vitamin D3 The treatment efficacy was monitored by doing lipid profile at first, third and sixth month of therapy.RESULTS: At the end of sixth month the mean total cholesterol was significantly reduced in atorvastatin vitamin D3 group than in atorvastatin group with ‘p’ value <0.001. The mean LDL–C, TG, VLDL were significantly reduced in atorvastatin vitamin D3 group than in atorvastatin group with ‘p’ value <0.001. The Atorvastatin and vitamin D3 treated group showed good response compared to atorvastatin treated group.